

### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Spellberg 1



Section 1. Identifying Inform	ation			
1. Given Name (First Name) Brad	2. Surname (Last Nar Spellberg	ne)		3. Date 09-August-2019
4. Are you the corresponding author?	✓ Yes No			
5. Manuscript Title Ensuring Sustainability of Needed Antib	iotics: Aiming for the	e DART Board		
6. Manuscript Identifying Number (if you kn M19-1893	ow it)			
Section 2. The Work Under Co				
The Work Under Co	onsideration for P	ublication		
Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?				
Are there any relevant conflicts of intere	st? Yes ✓	No		
Section 3. Relevant financial a	activities outside	the submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as describlicking the "Add +" box. You should rep	bed in the instruction	ns. Use one line fo	or each en	tity; add as many lines as you need by
Are there any relevant conflicts of intere	st? 🗸 Yes	No		
If yes, please fill out the appropriate info	rmation below.			
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments
Pfizer, Cempra, Bayer, Forge, Shionogi, Alexion, Synthetic Biologics, Paratek, Tetraphase, Merck GlaxoSmithKline, Peptilogics, and Acuryx			<b>✓</b>	Consulting fees
Bio AIM, ExBaq, Myco Med, Synthetic Biologics, Motif, and Nova Digm Therapeutics			<b>✓</b>	Equity
Section 4. Intellectual Proper	ty Patents & <u>Co</u>	oyrights		
Do you have any patents, whether planr			nt to the v	work?

Spellberg 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Merck, GlaxoSm	ports other from Pfizer, Cempra, Bayer, Forge, Shionogi, Alexion, Synthetic Biologics, Paratek, Tetraphase, thKline, Peptilogics, and Acuryx, other from BioAIM, ExBaq, MycoMed, Synthetic Biologics, Motif, and apeutics, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Spellberg 3



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

1

gilbert



Section 1.	Identifying Inform	nation				
1. Given Name (Fi david	rst Name)	2. Surname (Last Name) gilbert	3. Date 09-August-2019			
4. Are you the corresponding author?		Yes ✓ No	Corresponding Author's Name brad spellberg			
5. Manuscript Title ensuring sustain		iotics; aiming for the DAR	Board			
6. Manuscript Ider	ntifying Number (if you kr	now it)				
			-			
Section 2.	The Work Under Co	onsideration for Public	cation			
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,			
Section 3.	Dalamant Grannial					
Place a check in to of compensation clicking the "Add	the appropriate boxes i ) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.			
Section 4.	Intellectual Proper	rty Patents & Copyrig	ghts			
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No			

gilbert 2



Section 5.	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

gilbert 3



### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

# The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

# Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



### Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



	2 (	on o // o o b b/ `		
1. Given Name (First Name) Andrew	2. Surnai Shorr	me (Last Name)		3. Date 16-August-2019
4. Are you the corresponding author?	Yes	<b>✓</b> No	Corresponding Brad Spellber	g Author's Name
5. Manuscript Title Ensuring Sustanability of Needed And	tibiotics			
6. Manuscript Identifying Number (if you	know it)			
Section 2. The Work Under				
The Work Under	Considera	tion for Public	ation	
any aspect of the submitted work (includi statistical analysis, etc.)? Are there any relevant conflicts of inte	ng but not lim	nited to grants, da Yes ✓ No	ta monitoring bo	rernment, commercial, private foundation, etc.) f ard, study design, manuscript preparation,
Section 3. Relevant financia	ıl activities	outside the s	ubmitted wo	rk.
or compensation) with entities as desi	cribed in the	Instructions, Us	e one line for ea	financial relationships (regardless of amount ach entity; add as many lines as you need by
clicking the "Add +" box. You should r	eport relatio	nships that were	present durin	ng the 36 months prior to publication
licking the Add + box. You should r	eport relatio	nships that were es No	e <mark>present d</mark> urir	ng the 36 months prior to publication.
clicking the "Add +" box. You should r Are there any relevant conflicts of inte If yes, please fill out the appropriate in	eport relationerest?	es No	e present durir	ng the 36 months prior to publication.
Are there any relevant conflicts of inte	erest?	elow.  Personal Non	-Financial Ot	ng the 36 months prior to publication.
Are there any relevant conflicts of interference of the appropriate in	erest?  \square\ \	elow.  Personal Non Fees? Su	e present durir	ng the 36 months prior to publication.  ther? Comments
Are there any relevant conflicts of interference of the fyes, please fill out the appropriate in lame of Entity	erest?  \square\ \	elow.  Personal Non Fees? Su	-Financial Ot	the 36 months prior to publication.  Comments  Consulting
Are there any relevant conflicts of interference of the appropriate in lame of Entity  Are any relevant conflicts of interference of the appropriate in lame of Entity  Baogen	erest?  \square\ \	elow.  Personal Non Fees? Su	-Financial Ot	the 36 months prior to publication.  Comments  Consulting  Consulting
Are there any relevant conflicts of interference from the superior of the supe	eport relation press; vision p	Ves No	-Financial Ot	the 36 months prior to publication.  Comments  Consulting
Are there any relevant conflicts of interference from the superior of the supe	eport relation press; vision p	Yes No	-Financial Ot	her? Comments  Consulting  Consulting  Consulting  Consulting
Are there any relevant conflicts of inte	eport relation between the control of the control o	Yes No	-Financial Ot	her? Comments  Consulting  Consulting  Consulting  Consulting
Are there any relevant conflicts of interference of the second of the se	eport relation between the control of the control o	Yes No	-Financial Ot	consulting Consulting Consulting Consulting Consulting Consulting Consulting



Name of the		Personal	Non Financial		DARKS TO BE SEEN	25 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2	
Name of Entity	Grant?	Fees?	Non-Financial Support?	Other?	Comments		
Paratek		<b>V</b>	Support		Consulting		SEE
Shionogi		<b>V</b>			Consutling		
Spero	<b>V</b>				Consulting		
Tetraphase	<b>V</b>	✓			Consulting, educa	ation	
Wockhardt		<b>V</b>	П	Н	Consulting	ation	
Section 4. Intellectual Proposition Do you have any patents, whether pla				nt to the	work? Yes	<b>√</b> No	
Section 5. Relationships no	t covered	ahawa					
Are there other relationships or activit potentially influencing, what you wrot	ies that read	lers could n	erceive to have ink?	nfluence	d, or that give the	e appearance of	
Yes, the following relationships/co	nditions/circ	cumstances es that pres	are present (exp sent a potential c	lain belo	w): f interest		
At the time of manuscript acceptance, On occasion, journals may ask authors	journals will to disclose f	l ask author further infor	s to confirm and, rmation about re	, if necess ported re	sary, update thei elationships.	r disclosure statem	ents.
Section 6. Disclosure Statem	ient						
Based on the above disclosures, this fo below.		matically ge	enerate a disclosi	ure stater	ment, which will	appear in the box	
Dr Shorr has served as a consultant to, bearing on the content of the present	or re <mark>ceived</mark> work.	research su	pport from multi	iple comp	oanies as listed a	bove. They had no	>



## **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Nielsen 1



Section 1. Identifying Info	rmation	
1. Given Name (First Name) Travis	2. Surname (Last Name) Nielsen	3. Date 09-August-2019
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Brad Spellberg
5. Manuscript Title Ensuring Sustainability of Needed Ar	ntibiotics: Aiming for the DAF	RT Board
6. Manuscript Identifying Number (if you M19-1893	know it)	
Section 2. The Work Under	Consideration for Public	cation
	ing but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financi	al activities outside the s	submitted work.
of compensation) with entities as des	cribed in the instructions. Us report relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
If yes, please fill out the appropriate i		
Name of Entity	Grant? Personal Noi	on-Financial Other? Comments
BioAIM		<b>☐</b> Equity
xBaq		<b>☐</b> Equity
Section 4. Intellectual Prop	erty Patents & Copyri	ghts
Do you have any patents, whether pl	anned, pending or issued, br	roadly relevant to the work? Yes V No

Nielsen 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Nielsen reports other from BioAIM, other from ExBaq, outside the submitted work.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Nielsen 3



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation					
1. Given Name (Fil Eric	rst Name)	2. Surnan Brass	ne (Last Nar	ne)		3. Date 03-August-2019	
4. Are you the cor	responding author?	Yes	✓ No	Correspond Spellberg	ding Auth	or's Name	
5. Manuscript Title Ensuring Sustain	e ability of Needed Antib	iotics: Aim	ing for the	e DART Board			
6. Manuscript Ider M19-1893	ntifying Number (if you kn	ow it)					
Section 2.	The Work Under Co	onsiderat	ion for P	ublication			
any aspect of the s statistical analysis,	ubmitted work (including	but not lim		its, data monitoring		ent, commercial, private foundation, etcudy design, manuscript preparation,	c.) for
Section 3.	Relevant financial	activities	outside	the submitted	work.		
of compensation clicking the "Add Are there any rele	) with entities as descri	bed in the port relationst?	instructionnships tha	ns. Use one line fo	or each e	cial relationships (regardless of amo ntity; add as many lines as you need e 36 months prior to publication.	
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
_eadiant Biosciences					<b>✓</b>	Consultant	
Pfizer					<b>✓</b>	Consultant	
Johnson & Johnson					<b>✓</b>	Consultant	
Novo Nordisk					<b>✓</b>	Consultant	
3D Communications					✓	Advisory Board	
Bayer					<b>√</b>	Consultant	
Charleston Laborator	ies				<b>✓</b>	Consultant	
Akcea Therapeutics					<b>✓</b>	Consultant	



Name of Entity	Grant?	Personal	Non-Financial	Other?	Comments	
· ·		Fees?	Support?			
Acel Rx				✓	Consultant	
MedSurg PI				<b>✓</b>	Consultant	
HRA Pharma				<b>✓</b>	Consultant	
Chiesi Pharmaceuticals				<b>✓</b>	Consultant	
Consumer Healthcare Products Assoc				<b>✓</b>	Consultant	
Catabasis Pharmaceuticals				<b>✓</b>	Equity	
Calistoga Pharmaceuticals				<b>√</b>	Equity	
Do you have any patents, whether planr	ned, pend	ing or issue	ed, broadly releva	int to the	work? Yes No	
Section 5. Relationships not	covered	ahove				
Are there other relationships or activitie potentially influencing, what you wrote	s that read	ders could p		influence	d, or that give the appearance of	
Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						



### Section 6.

### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Brass reports other from Leadiant Biosciences, other from Pfizer, other from Johnson & Johnson, other from Novo Nordisk, other from 3D Communications, other from Bayer, other from Charleston Laboratories, other from Akcea Therapeutics, other from Acel Rx, other from MedSurg PI, other from HRA Pharma, other from Chiesi Pharmaceuticals, other from Consumer Healthcare Products Assoc, other from Catabasis Pharmaceuticals, other from Calistoga Pharmaceuticals, outside the submitted work;

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.